poisar

Stocks · News reference

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Fiscal.ai

BlossomHill Therapeutics announced its third-quarter 2026 financial results, highlighting FDA alignment on the Phase 2 dose for its lead candidate, BH-30643, and the initiation of the pivotal SOLARA-2 trial.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading